SecBot SecBot
8-K ·Filed Feb 26, 2026

VTRS

Viatris Inc
MIXED
Impact 7/10
Horizonweeks Processed8mo ago SEC0001792044-26-000010
Killer combo: Earnings + restructuring announcement
Actionable Insight ◆ Mixed

The stock may react positively to the 2026 growth guidance and cost savings plan, but investors should monitor the execution of the restructuring, resolution of the India manufacturing issues, and whether the recent quarterly revenue improvement can be sustained to reverse the full-year decline trend.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

VTRS drug pipeline →

norelgestromin/ethinyl estradiol weekly patch

● Neutral Named in this 8-K
Impact
Phase
Filed/PDUFA
Time to market
Approved product (Xulane) already on market since 2014. XULANE LO (low-dose version) PDUFA decision July 30, 2026 — potential launch H2 2026 if approved.
Next catalyst
None dated

What to watchWatch the July 30, 2026 PDUFA date for XULANE LO. If approved, the low-estrogen positioning and "best-in-class adhesion" claims could help Viatris capture share in the ~$1B+ contraceptive patch market. A CRL (complete response letter) would be a near-term negative but not company-threatening given Viatris's diversified portfolio. The stock is near its 52-week high (~$17.53) with 12 sell-side analysts averaging a $17.81 target, suggesting modest upside is already priced in.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.12
T+0 close · Feb 26, 2026 · via day close
Latest settled
+8.86%
T+60 · $16.46
Vs SPY
+1.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $15.12entry
  2. T+1 · 9mo ago −2.10%α −1.65% · $14.80
  3. T+5 · 9mo ago −4.72%α −3.59% · $14.41
  4. T+20 · 8mo ago −11.58%α −5.18% · $13.37
  5. T+60 · 6mo ago +8.86%α +1.11% · $16.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Viatris reported mixed financial results for 2025, with full-year revenue declining 3% YoY but fourth-quarter revenue growing 5% YoY. The company announced a major restructuring expected to incur $700M-$850M in charges to achieve $650M in cost savings, while also revealing a fire at its Nashik, India manufacturing facility. Despite the operational challenges, management provided 2026 guidance projecting revenue growth to $14.45B-$14.95B and positioned the company for a turnaround.

Key Financial Metrics

Revenue
$14.3B
-3.0% YoY
Adj. EPS
$2.35
GAAP: $-3.00
Guidance
$14,450 - $14,950
provided
Free Cash Flow
$1.9B
Gross Margin
35.1%

Key Facts

  • Full-year 2025 revenue declined 3% YoY to $14.3B, with generics revenue down 8% and brands revenue flat
  • Fourth-quarter revenue grew 5% YoY to $3.7B, showing recent improvement
  • Company announced restructuring with $700M-$850M in charges to achieve $650M in cost savings
  • Fire at Nashik, India manufacturing facility temporarily suspended operations with expected resumption in April 2026
  • 2026 guidance projects revenue of $14.45B-$14.95B and adjusted EPS of $2.33-$2.47
  • Adjusted EPS declined 11% YoY to $2.35 in 2025

Financial Impact

Restructuring charges of $700M-$850M expected to yield $650M in cost savings; 2026 revenue guidance of $14.45B-$14.95B represents 1-5% growth over 2025

revenueepsmarginscashFlowrestructuring costs

Segment Breakdown

SegmentRevenueGrowth
Brands$9.2B-0.2%
Generics$5.1B-7.7%

Risk Factors

  • Execution risk on the major restructuring plan
  • Ongoing manufacturing issues at India facilities impacting supply
  • Declining generics business (-8% YoY) and flat brands revenue
  • High debt levels with $12.5B in long-term debt

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001792044-26-000010
Document: vtrs-20260223.htm0001792044-26-000010
Document: 0001792044-26-000010-index-headers.html0001792044-26-000010
Document: 0001792044-26-000010-index.html0001792044-26-000010
Document: 0001792044-26-000010.txt0001792044-26-000010

US Market Status

Market Open · Closes in 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026